Europe
Plenty of biotech companies will be releasing their third-quarter financial reports next week. Let’s take a quick look at some of these companies and their top stories they reported through 3Q2018.
Shares of Bone Therapeutics have plunged more than 26 percent on the Euronext Brussels stock exchange after the Belgium-based company halted a Phase III trial in osteonecrosis of the hip after an interim analysis indicated the study would not meet endpoints.
NOXXON Pharma N.V. announced today that it will report top-line efficacy data from the ongoing clinical trial (NCT03168139) testing NOX-A12 (olaptesed pegol) in combination with Merck & Co./MSD’s PD-1 inhibitor Keytruda® in metastatic, microsatellite stable pancreatic and colorectal cancer patients at the ESMO Immuno-Oncology Conference taking place in Geneva, Switzerland, December 13-16, 2018.
Novo Seeds invests €12.5 million becoming largest shareholder
Sareum Holdings plc announces that it has raised £850,000, before expenses, through a placement of 130,769,231 new ordinary shares of 0.025p each in the capital of the Company (the “Placing Shares”) through a third party licensed dealer acting solely as a placing agent to this transaction at 0.65p per share.
Pharnext SA announced today its financial results for first-half 2018.
PARAS BIOPHARMACEUTICALS FINLAND OY is currently enhancing its GMP, quality systems and production facilities for biopharmaceuticals – also known as biologics – with significant investments in new infrastructure and equipment.
Technology supported by Dr Jonathan Milner in his ELRIG Plenary Address
Janssen agreed to pay Yuhan $50 million in upfront money. Yuhan said that Janssen will be responsible for the development of lazertinib. Janssen will also be responsible for manufacturing and commercialization of the drug.
AstraZeneca is unloading rights to Alvesco (ciclesonide) to treat persistent asthma, and Omnaris and Zetonna (ciclesonide) to treat nasal symptoms associated with rhinitis. The company indicates that the rights cover markets outside the United States and the U.S. royalties for the drugs.
PRESS RELEASES